Relief Therapeutics Advances Publication of 2025 Half-Year Report
Relief Therapeutics (OTCQB:RLFTY), a biopharmaceutical company focused on specialty and rare diseases, has moved up the publication date of its 2025 half-year report. The report will now be released on August 14, 2025, before market opening, instead of the originally planned date of August 27, 2025.
The earlier publication is attributed to the anticipated early completion of the report. The half-year report will contain interim financial statements and a shareholder update, which will be accessible on Relief's website upon release.
Relief Therapeutics (OTCQB:RLFTY), una società biofarmaceutica specializzata in malattie rare e terapie di nicchia, ha anticipato la pubblicazione del proprio rapporto semestrale 2025. Il rapporto sarà ora pubblicato il 14 agosto 2025, prima dell'apertura dei mercati, anziché il 27 agosto 2025 come inizialmente previsto.
L'anticipazione deriva dal previsto completamento anticipato del rapporto. Il semestrale conterrà bilanci finanziari provvisori e un aggiornamento per gli azionisti, che saranno disponibili sul sito web di Relief al momento della pubblicazione.
Relief Therapeutics (OTCQB:RLFTY), una compañía biofarmacéutica centrada en enfermedades raras y especializadas, ha adelantado la fecha de publicación de su informe semestral 2025. El informe se publicará ahora el 14 de agosto de 2025, antes de la apertura del mercado, en lugar del 27 de agosto de 2025 inicialmente previsto.
El adelanto se debe a la previsión de una finalización anticipada del informe. El informe semestral incluirá estados financieros interinos y una actualización para los accionistas, que estarán disponibles en la web de Relief tras su publicación.
Relief Therapeutics (OTCQB:RLFTY)는 희귀질환 및 전문 치료 분야에 주력하는 바이오제약사로, 2025년 반기보고서의 공개일을 앞당겼습니다. 해당 보고서는 당초 예정된 2025년 8월 27일이 아닌 2025년 8월 14일 장 개장 전 공개됩니다.
공개일이 앞당겨진 이유는 보고서의 조기 완료가 예상되기 때문입니다. 반기보고서에는 중간 재무제표와 주주 대상 업데이트가 포함되며, 공개 즉시 Relief 웹사이트에서 확인할 수 있습니다.
Relief Therapeutics (OTCQB:RLFTY), une société biopharmaceutique spécialisée dans les maladies rares et les traitements de niche, a avancé la date de publication de son rapport semestriel 2025. Le rapport sera désormais publié le 14 août 2025, avant l'ouverture des marchés, au lieu du 27 août 2025 initialement prévu.
Cette avance s'explique par l'achèvement prévu du rapport plus tôt. Le rapport semestriel contiendra des états financiers intermédiaires et une mise à jour destinée aux actionnaires, qui seront accessibles sur le site de Relief au moment de la publication.
Relief Therapeutics (OTCQB:RLFTY), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Spezial- und Seltenkrankheiten, hat das Veröffentlichungsdatum seines Halbjahresberichts 2025 vorverlegt. Der Bericht wird nun am 14. August 2025, vor Handelsbeginn, veröffentlicht statt wie ursprünglich geplant am 27. August 2025.
Grund für die Vorverlegung ist die erwartete frühere Fertigstellung des Berichts. Der Halbjahresbericht enthält vorläufige Finanzabschlüsse und ein Aktionärsupdate, das nach Veröffentlichung auf der Website von Relief verfügbar sein wird.
- None.
- None.
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.
The change in publication date is due to the Company's anticipated early completion of the report. The half-year report, which will include a shareholder update and interim financial statements, will be available on Relief's website at the time of publication.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
When will Relief Therapeutics (RLFTY) release its 2025 half-year report?
Where can investors access Relief Therapeutics' 2025 half-year report?
What will be included in Relief Therapeutics' 2025 half-year report?
Why did Relief Therapeutics change the publication date of its half-year report?
